Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON-Neuroblastoma: bevacizumab added to temozolomide ± irinotecan/topotecan in relapsed/refractory pediatric neuroblastoma
2012-000072-42Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Feb 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab in neuroblastoma (3 arms), sponsored by University of Birmingham. Primary endpoint: Best response. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2012-000072-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000072-42.